

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

23 Feb 2026

### Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial

#### Protocol summary

##### Study aim

Determining effect of Convalescent Plasma on COVID-19 patients Outcome: A Randomised Clinical Trial

##### Design

The clinical trial has an intervention group without blinding and randomization

##### Settings and conduct

After the call for the donation of the convalescent plasma by the recently recovered patients, about 450 ml of the received plasma will be transferred to the COVID-19 patients hospitalized in the ICU of Imam Khomeini Hospital in Sari.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: Recipient: 1- COVID-19 Patients 2- Consent to attend the study 3. Age 30 to 70 years 4- Don't be intubated 5- PaO<sub>2</sub> / FiO<sub>2</sub> is above 200 or Spo<sub>2</sub> is greater than 85%. Donator: 1- Complete recovery from severe COVID-19 disease and hospital discharge 2- Consent to donate blood to the infected person 3- Age 30 to 60 years 4- Has normal CBC test results 5. Negative COVID-19 RT-PCR test Exclusion criteria: Recipient: 1. A history of hypersensitivity to blood transfusions or its products 2. History of IgA deficiency 3. Heart failure or any other factor that prevents the injection of of 500 ml plasma 4. Entering the intubation stage Donator: 1- Patients infected with blood-borne viral / infectious diseases 2 - Underlying heart disease, low or high blood pressure, diabetes, epilepsy, and anything that may prohibit blood donation. 3. Use of banned drugs for blood donation (eg, ethertinate, acitretin, aliotretinoin, isotretinoin, antiandrogens, NSAIDs, etc.) 4- Use of different drugs 5. Other prohibited donations based on blood transfusion standards

##### Intervention groups

Intervention to evaluate convalescent plasma transfer to COVID-19 patients admitted to ICU

##### Main outcome variables

1- 10-day mortality 2- 30-day mortality 3. Inflammatory factors 4- PaO<sub>2</sub> / FiO<sub>2</sub>

#### General information

##### Reason for update

A change in English title

##### Acronym

COVID 19

##### IRCT registration information

IRCT registration number: **IRCT20181104041551N1**

Registration date: **2020-03-24, 1399/01/05**

Registration timing: **prospective**

Last update: **2020-04-12, 1399/01/24**

Update count: **1**

##### Registration date

2020-03-24, 1399/01/05

##### Registrant information

###### Name

Fateme Heydari

###### Name of organization / entity

###### Country

Iran (Islamic Republic of)

###### Phone

+98 11 3336 1700

###### Email address

f.heydari@mazums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2020-03-28, 1399/01/09

##### Expected recruitment end date

2020-05-20, 1399/02/31

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

## Scientific title

Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial

## Public title

Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial

## Purpose

Treatment

## Inclusion/Exclusion criteria

### Inclusion criteria:

COVID-19 Patients Consent to attend the study Do not be intubated PaO<sub>2</sub> / FiO<sub>2</sub> above 200 or Spo<sub>2</sub> above 85%

### Exclusion criteria:

A history of hypersensitivity to blood transfusions or its products History of IgA deficiency Heart failure or any factor that prevent from getting 500ml of plasma Entering the intubation stage

## Age

From **30 years** old to **70 years** old

## Gender

Both

## Phase

N/A

## Groups that have been masked

*No information*

## Sample size

Target sample size: **30**

## Randomization (investigator's opinion)

N/A

## Randomization description

## Blinding (investigator's opinion)

Not blinded

## Blinding description

## Placebo

Not used

## Assignment

Single

## Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics Committee of Mazandaran University of Medical Sciences

##### Street address

Vice-Chancellor for research, Mazandaran University of Medical Sciences, Moallem Sq.

##### City

Sari

##### Province

Mazandaran

##### Postal code

4817844718

#### Approval date

2020-03-23, 1399/01/04

## Ethics committee reference number

IR.MAZUMS.REC.1399.7330

## Health conditions studied

### 1

#### Description of health condition studied

COVID-19

#### ICD-10 code

B34.2

#### ICD-10 code description

Coronavirus infection, unspecified

## Primary outcomes

### 1

#### Description

Mortality

#### Timepoint

10 days and 30 days after intervention

#### Method of measurement

Measure of the number of deaths in a particular population, scaled to the size of that population, per unit of time.

### 2

#### Description

Inflammatory factors

#### Timepoint

Days 1, 3 and 7

#### Method of measurement

The enzyme-linked immunosorbent assay

### 3

#### Description

Partial pressure of arterial oxygen/Percentage of inspired oxygen

#### Timepoint

Days 1, 3, 7

#### Method of measurement

Partial pressure of arterial oxygen/Percentage of inspired oxygen

## Secondary outcomes

### 1

#### Description

Length of hospitalization

#### Timepoint

End of study

#### Method of measurement

Day number

### 2

#### Description

Days of mechanical ventilation

**Timepoint**

End of study

**Method of measurement**

Day number

**3**

**Description**

Leukocyte and lymphocyte count

**Timepoint**

Days 1, 3, 7

**Method of measurement**

Complete blood count test

**4**

**Description**

CD3, CD4, CD8 cell count and CD4 / CD8 ratio

**Timepoint**

Days 1, 3, 7

**Method of measurement**

Flow Cytometry

**5**

**Description**

Function and changes of liver enzymes

**Timepoint**

Days 1, 3, 7

**Method of measurement**

Biochemical tests

**6**

**Description**

Cardiac enzyme function and changes

**Timepoint**

Days 1, 3, 7

**Method of measurement**

Biochemical tests

**7**

**Description**

Specific IgG

**Timepoint**

Days 1, 3, 7

**Method of measurement**

The enzyme-linked immunosorbent assay

**8**

**Description**

Radiological findings

**Timepoint**

Admitted time and day 14

**Method of measurement**

Computed tomography Scan and Chest X-Ray

**Intervention groups**

**1**

**Description**

Intervention group: COVID-19 patients who are hospitalized in the ICU, according to the blood type, receive about 450 ml of plasma received from COVID-19 patients who have recently recovered.

**Category**

Treatment - Other

**Recruitment centers**

**1**

**Recruitment center**

**Name of recruitment center**

Imam Khomeini Educational Hospital, Sari

**Full name of responsible person**

Fatemeh Heidari

**Street address**

Imam Khomeini Educational Hospital, Razi St.

**City**

Sari

**Province**

Mazandaran

**Postal code**

4816633131

**Phone**

+98 11 3336 1700

**Email**

F.Heydari@mazums.ac.ir

**Web page address**

<http://imamhospital.mazums.ac.ir/>

**Sponsors / Funding sources**

**1**

**Sponsor**

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Professor Majid Saeedi

**Street address**

Vice-Chancellor for research, Mazandaran University of Medical Sciences, Moallem Sq.

**City**

Sari

**Province**

Mazandaran

**Postal code**

4817844718

**Phone**

+98 11 3448 4800

**Email**

msaeedi@mazums.ac.ir

**Grant name**

**Grant code / Reference number**

**Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Mazandaran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

*empty*

**Country of origin**

**Type of organization providing the funding**

Academic

## Person responsible for general inquiries

**Contact**

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Fatemeh Heidari

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Imam Khomeini Educational Hospital, Razi Sq.

**City**

Sari

**Province**

Mazandaran

**Postal code**

4816633131

**Phone**

+98 11 3336 1700

**Email**

F.Heydari@mazums.ac.ir

## Person responsible for scientific inquiries

**Contact**

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Fatemeh Heidari

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Imam Khomeini Hospital, Razi Sq.

**City**

Sari

**Province**

Mazandaran

**Postal code**

4816633131

**Phone**

011 3361700

**Email**

F.Heydari@mazums.ac.ir

## Person responsible for updating data

**Contact**

**Name of organization / entity**

Mazandaran University of Medical Sciences

**Full name of responsible person**

Fatemeh Heidari

**Position**

Assistant Professor

**Latest degree**

Specialist

**Other areas of specialty/work**

Anesthesiology

**Street address**

Imam Khomeini Hospital, Razi Sq.

**City**

Sari

**Province**

Mazandaran

**Postal code**

4816633131

**Phone**

+98 11 3336 1700

**Email**

F.Heydari@mazums.ac.ir

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Not applicable

**Title and more details about the data/document**

SPSS data can be shared.

**When the data will become available and for how long**

Post publication

**To whom data/document is available**

Researcher

**Under which criteria data/document could be used**

Use for review study

**From where data/document is obtainable**

Corresponding author email

**What processes are involved for a request to access data/document**

Request via email

## Comments